Mid Atlantic Financial Management Inc. ADV Cuts Position in Amedisys Inc (NASDAQ:AMED)

Mid Atlantic Financial Management Inc. ADV Cuts Position in Amedisys Inc (NASDAQ:AMED)

  • August 28, 2020
  • 0 comments

Mid Atlantic Financial Management Inc. ADV lessened its position in shares of Amedisys Inc (NASDAQ:AMED) by 2.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,740 shares of the health services provider’s stock after selling 45 shares during the quarter. Mid Atlantic Financial Management Inc. ADV’s holdings in Amedisys were worth $345,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMED. Smithfield Trust Co. purchased a new position in Amedisys during the 1st quarter valued at approximately $27,000. Cullen Frost Bankers Inc. purchased a new position in shares of Amedisys in the 2nd quarter worth approximately $41,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Amedisys in the 1st quarter worth approximately $60,000. Anderson Fisher LLC purchased a new position in shares of Amedisys in the 1st quarter worth approximately $67,000. Finally, Fort L.P. purchased a new position in shares of Amedisys in the 1st quarter worth approximately $118,000. Institutional investors and hedge funds own 88.31% of the company’s stock.

AMED has been the subject of a number of recent research reports. UBS Group dropped their target price on Amedisys from $208.00 to $190.00 and set a “neutral” rating for the company in a report on Monday, May 11th. Oppenheimer reiterated a “buy” rating and issued a $215.00 target price on shares of Amedisys in a report on Monday, April 27th. Royal Bank of Canada lifted their target price on Amedisys from $218.00 to $260.00 and gave the stock an “outperform” rating in a report on Thursday, July 30th. Benchmark raised their price target on Amedisys from $210.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Finally, Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $193.00 price target for the company in a research note on Friday, May 1st. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $222.14.

Shares of NASDAQ AMED opened at $233.50 on Tuesday. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.63. The business has a fifty day simple moving average of $217.44 and a two-hundred day simple moving average of $191.91. The firm has a market cap of $7.48 billion, a PE ratio of 60.49, a price-to-earnings-growth ratio of 3.26 and a beta of 0.98. Amedisys Inc has a twelve month low of $121.00 and a twelve month high of $239.49.

Amedisys (NASDAQ:AMED) last issued its earnings results on Tuesday, July 28th. The health services provider reported $1.34 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.53. The business had revenue of $485.06 million during the quarter, compared to analyst estimates of $468.38 million. Amedisys had a return on equity of 22.41% and a net margin of 6.50%. Amedisys’s revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the company posted $1.21 EPS. On average, research analysts expect that Amedisys Inc will post 5.01 earnings per share for the current year.

In other news, COO Christopher Gerard sold 750 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $189.42, for a total value of $142,065.00. Following the completion of the transaction, the chief operating officer now directly owns 33,926 shares of the company’s stock, valued at approximately $6,426,262.92. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider David L. Kemmerly sold 2,209 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $176.81, for a total value of $390,573.29. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,006 shares of company stock valued at $1,366,751. 2.80% of the stock is currently owned by corporate insiders.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Article: Consumer behavior in bull markets

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amedisys and related companies with MarketBeat.com’s FREE daily email newsletter.

Source Article